Physician profile
Minsig Choi
NPI 1073629812
$348,300.60
in general payments reported to CMS, 2019-2025
39 companies · $46K in 2025
The $46K reported for 2025 was more than what 95% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77K · 2020: $29K · 2021: $31K · 2022: $57K · 2023: $62K · 2024: $46K · 2025: $46K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $92K · Consulting Fee: $34K · Travel and Lodging: $15K · Food and Beverage: $6,960 · Honoraria: $6,450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $91,712.00 |
| Consulting Fee | $34,206.50 |
| Travel and Lodging | $14,783.95 |
| Food and Beverage | $6,959.64 |
| Honoraria | $6,450.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $141,045.76 | 2019-2025 | Opdivo |
| Genentech USA, INC. | $39,326.04 | 2019-2023 | Tecentriq |
| Ipsen Biopharmaceuticals, INC | $28,959.71 | 2019-2025 | Onivyde |
| Eisai INC. | $20,914.68 | 2019-2024 | |
| Exelixis INC. | $19,728.76 | 2019-2022 | |
| Amgen INC. | $16,094.37 | 2019-2020 | |
| Lilly USA, LLC | $15,750.00 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $12,402.71 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $7,445.68 | 2019-2021 | |
| Deciphera Pharmaceuticals INC. | $7,384.51 | 2024 | Qinlock |
| Gilead Sciences, INC. | $5,305.32 | 2025 | |
| Celgene Corporation | $5,093.15 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $4,414.92 | 2021-2025 | Lynparza, Imfinzi |
| Avyxa Pharma, LLC | $4,072.41 | 2025 | |
| Jazz Pharmaceuticals INC. | $3,398.69 | 2025 |
Show all 37 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minsig Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.